Sources and Guidelines Referenced

Clinical information presented in this guide is derived from established professional guidelines and peer-reviewed studies: American College of Obstetricians and Gynecologists (ACOG Practice Bulletin No. 228, 2021; Practice Bulletin No. 192, 2018); American Society for Reproductive Medicine (ASRM Practice Committee, 2021); National Institute for Health and Care Excellence (NICE Guideline NG100, 2018; updated 2021); European Society of Human Reproduction and Embryology (ESHRE Guideline on Endometriosis and Fibroids, 2020); Society of Obstetricians and Gynaecologists of Canada (SOGC Guideline No. 389, 2019); FEMME Trial (Manyonda et al., New England Journal of Medicine, 2020); Cochrane Database of Systematic Reviews (Bhave Chittawar et al., 2014).

Myomectomy (Fibroid Removal): A Comprehensive Patient Guide

1. Definition and Medical Identity

A myomectomy is a specialized surgical procedure designed to excise benign uterine smooth muscle tumors, called uterine fibroids or leiomyomas, while leaving the body of the uterus fully intact. It belongs to the specialty of gynecologic surgery and represents the definitive organ-sparing operation for symptomatic fibroids.

The principal objective of a myomectomy is to eliminate fibroid tissue, alleviate debilitating symptoms such as menorrhagia and pelvic pain, restore structural integrity to the myometrium and endometrial cavity, and preserve future reproductive potential. The surgical term varies according to the operative approach utilized: hysteroscopic myomectomy (transvaginal approach through the cervix), laparoscopic myomectomy (keyhole abdominal surgery), robotic-assisted laparoscopic myomectomy (computer-assisted minimally invasive surgery), and abdominal myomectomy (open laparotomy). In clinical practice, myomectomy serves as the gold-standard alternative to hysterectomy (surgical removal of the uterus) for individuals seeking to retain their fertility or preserve their uterine anatomy (ACOG Practice Bulletin No. 228, 2021).

2. The Underlying Condition or Need

Uterine fibroids are noncancerous monoclonal tumors arising from the smooth muscle cells of the myometrium. They are the most common solid pelvic neoplasms in individuals of reproductive age, driven by cyclic exposure to the ovarian steroid hormones oestrogen and progesterone.

Fibroids disrupt pelvic function through several biological mechanisms. Submucosal fibroids distort the endometrial cavity, triggering vascular dysregulation and impairing localized myometrial contractility. This directly leads to menorrhagia (abnormally heavy or prolonged menstrual bleeding), which frequently causes severe iron-deficiency anaemia. Intramural and subserosal fibroids enlarge the overall dimensions of the uterus, exerting compressive force on adjacent retroperitoneal and pelvic structures. Patients commonly present with urinary frequency, urgency, incomplete bladder emptying, chronic pelvic pressure, back pain, and constipation. Fibroids that distort the endometrial lining or block the fallopian tube ostia can cause mechanical infertility, implantation failure, and recurrent early pregnancy loss (ASRM Practice Committee, 2021).

Left untreated, symptomatic fibroids tend to progress in size during the reproductive years. Persistent heavy bleeding can result in severe hemodynamic instability and profound fatigue from chronic anaemia. Progressive enlargement can lead to pelvic mass effect, hydronephrosis due to ureteral compression, and worsening pelvic pain. During pregnancy, untreated fibroids can undergo red degeneration—an acute hemorrhagic necrosis caused by rapid tumor growth outstripping its blood supply—leading to severe localized pain, pre-term labor, and delivery complications.

3. How the Treatment Works — Mechanism

Myomectomy works by dissecting and removing leiomyomatous tissue directly out of its surrounding cellular envelope, known as the pseudocapsule, followed by careful myometrial repair and uterine reconstruction.

At the cellular level, fibroids consist of proliferating smooth muscle cells embedded within an exaggerated extracellular matrix composed of collagen, fibronectin, and proteoglycans. During surgery, the clinician incises the overlying myometrium or endometrium to reach the distinct vascular boundary of the fibroid. Using blunt and sharp dissection, the surgeon enucleates the tumor from the surrounding healthy muscle tissue. Once the leiomyoma is completely removed, the remaining healthy myometrial tissue is closed in multiple surgical layers using absorbable sutures. Multi-layer closure eliminates empty anatomical spaces (dead space), prevents localized hematoma formation, ensures robust uterine wall strength, and achieves surgical haemostasis (cessation of bleeding).

In hysteroscopic procedures, fluid distension expands the uterine cavity, allowing an electrocautery loop or mechanical tissue removal device to shave away submucosal fibroid tissue level with the surrounding myometrial wall. Eliminating the tumor restores normal endometrial surface area, regular vascular response, and functional myometrial contractions during menstruation (NICE Guideline NG100, 2021).

4. Types and Variations

The choice of myomectomy technique depends on the size, number, and FIGO location of the fibroids, as well as the patient's prior surgical history and personal preferences.

There are four primary surgical variations of myomectomy utilized in modern clinical practice:

Surgical Technique	Primary Indication	FIGO Fibroid Types	Hospital Stay	Recovery Duration
Hysteroscopic Myomectomy	Intracavitary and submucosal fibroids ≤4 cm	Types 0, 1, 2	Outpatient (0 days)	24–48 hours
Laparoscopic Myomectomy	1 to 4 intramural or subserosal fibroids ≤8 cm	Types 3, 4, 5, 6	0–1 day	2–4 weeks
Robotic-Assisted Myomectomy	Multiple or complex intramural fibroids ≤10 cm	Types 2–6	0–1 day	2–4 weeks
Abdominal Myomectomy (Laparotomy)	Numerous (>5), very large (>10 cm), or deep fibroids	Types 2–7	2–3 days	6–8 weeks

Clinicians select the optimal approach by evaluating pre-operative imaging. Hysteroscopy is chosen for intracavitary tumors. Laparoscopic and robotic approaches are selected for moderate-sized intramural or subserosal fibroids due to reduced post-operative pain, shorter hospital stays, and minimal scarring. Abdominal myomectomy remains the standard of care for high tumor burdens or large fibroids requiring complex myometrial reconstruction (ACOG Practice Bulletin No. 228, 2021).

5. Who the Treatment Is For — Indications

Myomectomy is indicated for individuals with symptomatic uterine fibroids who wish to retain their fertility, preserve their uterus, or avoid hysterectomy.

Specific clinical indications established by ACOG and ASRM guidelines include:

• Abnormal Uterine Bleeding: Heavy, prolonged, or irregular menstrual bleeding causing anaemia or refractory to medical therapy.
• Symptomatic Pelvic Mass Effect: Bulk-related symptoms including chronic pelvic pain, urinary frequency, hydronephrosis, or bowel displacement.
• Reproductive Impairment: Documented infertility or recurrent pregnancy loss associated with submucosal or cavity-distorting intramural fibroids (FIGO Types 0, 1, 2, and select Type 3).
• Rapidly Growing Fibroids: Enlarging uterine mass causing clinical symptoms or diagnostic uncertainty.

Diagnostic workup requires transvaginal pelvic ultrasonography, augmented by contrast saline-infusion sonography (SIS) or diagnostic hysteroscopy for cavitary evaluation. Pelvic MRI is indicated when soft-tissue resolution is needed to map numerous fibroids prior to minimally invasive surgery. Pre-operative hemoglobin optimization is required for patients presenting with moderate to severe anaemia (SOGC Guideline No. 389, 2019).

6. Who the Treatment Is NOT For — Contraindications

While myomectomy is a highly effective procedure, specific clinical circumstances make it unsuitable or unsafe.

Absolute contraindications include:

• Suspected or Confirmed Malignancy: Presence of uterine leiomyosarcoma, endometrial carcinoma, or suspected pelvic malignancy. Tissue morcellation in the presence of occult leiomyosarcoma significantly worsens cancer prognosis (FDA Safety Communication, 2020).
• Active Pelvic Infection: Untreated acute pelvic inflammatory disease (PID), cervicitis, or active endometritis.
• Severe Medical Comorbidities: Inability to tolerate general anaesthesia or severe uncorrected coagulopathy.

Relative contraindications requiring surgical modification or medical pre-treatment include extensive pelvic adhesive disease, severe diffuse adenomyosis, extreme fibroid burden where complete resection would compromise functional myometrial integrity, and lack of desire for future fertility when less invasive or definitive options (such as hysterectomy) are preferred by the patient (ACOG Practice Bulletin No. 228, 2021).

7. Alternatives and Clinical Comparison

Several non-surgical, minimally invasive, and definitive surgical alternatives exist for managing symptomatic uterine fibroids.

['Potential adverse effect on ovarian reserve']

Treatment Option	Mechanism	Invasiveness	Fertility Preservation	Primary Trade-Off
Myomectomy	Surgical excision of fibroids	Surgical (Invasive)	Yes (Gold Standard)	Surgical risks, potential for recurrence
Hysterectomy	Complete removal of uterus	Surgical (Invasive)	No (Definitive)	Permanent loss of fertility
Uterine Artery Embolization (UAE)	Ischemic necrosis via arterial blockage	Minimally Invasive	Relative / Discouraged
GnRH Antagonists / Agonists	Systemic hormonal suppression	Non-Invasive (Medical)	Temporary	Symptom rebound upon discontinuation
Radiofrequency Ablation (RFA)	Thermal tissue necrosis via probe	Minimally Invasive	Under Study	Long-term pregnancy safety data limited

Clinicians recommend myomectomy over uterine artery embolization or radiofrequency ablation when preservation of future fertility is the primary treatment goal. The landmark FEMME trial (Manyonda et al., NEJM, 2020) demonstrated that while both myomectomy and UAE significantly improve quality of life, myomectomy provides superior clinical outcomes for symptom relief and lower secondary intervention rates over 2 years in reproductive-aged individuals.

8. Pre-Treatment Phase

The pre-treatment phase focuses on precise anatomical mapping, correcting systemic imbalances, and preparing the uterine tissue for surgery.

Initial consultation involves a detailed medical history focusing on bleeding patterns, reproductive plans, and pain scores. Laboratory workup includes a complete blood count, ferritin levels, type and screen, and coagulation profiles. If severe anaemia is present (hemoglobin <10 g/dL), pre-operative medical therapy is initiated. Administration of GnRH agonists (e.g., leuprolide acetate) or GnRH antagonists (e.g., relugolix) for 1 to 3 months prior to surgery induces a temporary hypoestrogenic state. This therapy reduces fibroid volume by 30% to 50%, decreases vascularity to minimize intraoperative blood loss, and allows iron restoration before open or laparoscopic surgery (ACOG Practice Bulletin No. 192, 2018).

Patients undergo formal informed consent discussing surgical risks, the rare possibility of emergency hysterectomy, and alternative options. Fasting guidelines require abstaining from solid foods for 8 hours and clear fluids for 2 hours prior to general anaesthesia. Antiplatelet medications and nonsteroidal anti-inflammatory drugs (NSAIDs) are held 7 to 10 days before surgery under medical supervision.

9. The Procedure — Step-by-Step Clinical Detail

The surgical execution of myomectomy follows a structured clinical protocol tailored to the chosen approach.

Laparoscopic / Robotic Myomectomy Protocol

1. Anaesthesia and Positioning: General endotracheal anaesthesia is administered. The patient is placed in the low lithotomy position with arms tucked. A Foley catheter decompresses the bladder.
2. Access and Pneumoperitoneum: A primary umbilical incision allows insertion of a laparoscope under direct visualization. Transabdominal micro-incisions (5–12 mm) are placed in the lower abdomen to introduce surgical instruments. The abdomen is insufflated with carbon dioxide gas.
3. Uterine Infiltration and Incision: A dilute vasopressin solution is injected directly into the myometrium surrounding the fibroid to induce localized vasoconstriction and reduce blood loss. A linear incision is made through the myometrium down to the fibroid pseudocapsule using electrocautery.
4. Enucleation: Tenacula and traction-countertraction instruments grip the fibroid while blunt and sharp dissection strips away the pseudocapsule, freeing the tumor.
5. Myometrial Reconstruction: The surgical defect is closed in multiple continuous layers using barbed absorbable sutures to ensure precise reapproximation of uterine tissue and prevent hematoma formation.
6. Tissue Extraction: Fibroid tissue is placed inside a heavy-duty specimen retrieval bag and extracted through an enlarged incision or via contained manual tissue morcellation.
7. Hemostasis and Closure: The pelvis is irrigated, hemostasis is verified, anti-adhesion barriers are placed, instruments are removed, and skin incisions are closed with subcuticular sutures.

Hysteroscopic Myomectomy Protocol

Performed under conscious sedation or general anaesthesia. The cervix is dilated, and a hysteroscopic resectoscope is inserted into the uterine cavity under fluid distension (using non-conductive or isotonic fluid). A bipolar wire loop or mechanical hysteroscopic tissue removal system progressively resects the submucosal fibroid down to the surrounding normal myometrial margin. No abdominal incisions are required.

10. Immediate Post-Procedure Period

The immediate post-operative period focuses on monitoring hemodynamic stability, managing incisional pain, and preventing acute complications.

Patients transition to the Post-Anesthesia Care Unit (PACU) for continuous monitoring of vital signs, oxygen saturation, and urine output. Early pain management is delivered through a multimodal regimen combining intravenous acetaminophen, nonsteroidal anti-inflammatory drugs (ketorolac), and short-acting opioids if necessary. Nausea is managed with intravenous antiemetics (ondansetron).

Discharge criteria for outpatient or short-stay admissions include stable vital signs, adequate pain control on oral medications, ability to tolerate oral fluids, spontaneous urinary voiding following catheter removal, and unassisted ambulation. Patients undergoing hysteroscopic myomectomy are typically discharged within 2 to 4 hours. Patients undergoing abdominal or complex robotic myomectomy remain hospitalized for 24 to 72 hours for active monitoring of surgical site healing and bowel function (SOGC Guideline No. 389, 2019).

11. Recovery — Short and Long Term

Recovery times vary based on the surgical approach, physical baseline, and extent of uterine reconstruction.

The recovery timeline across approaches is detailed below:

• Days 1–3: Transition from oral pain medications to over-the-counter analgesics. Light walking is encouraged to reduce the risk of deep vein thrombosis (DVT). Mild vaginal spotting and light abdominal cramping are expected.
• Weeks 1–2: Incisions heal. Patients undergoing hysteroscopic or laparoscopic procedures resume light daily activities and desk-based work. Driving is permitted once narcotic pain medications are discontinued and abdominal reaction time is normal.
• Weeks 3–4: Laparoscopic and robotic patients return to full daily work and light exercise routines. Heavy lifting (>10–15 lbs) remains restricted.
• Weeks 6–8: Open abdominal myomectomy patients complete incisional healing and resume full physical activity, including strenuous exercise. Sexual intercourse, pelvic baths, and tampon use may resume following clinical clearance at the 6-week visit.

A routine post-operative evaluation occurs at 2 and 6 weeks. For patients planning pregnancy, a healing period of 3 to 6 months is mandatory following myomectomy involving deep myometrial incisions to allow optimal collagen deposition and muscular healing (ACOG Practice Bulletin No. 228, 2021).

12. Risks, Side Effects, and Complications

As with all major surgical interventions, myomectomy carries potential risks and adverse effects, stratified by clinical severity.

Severity Level	Potential Complications	Incidence Rate	Clinical Management
Common / Mild	Transient incisional pain, light vaginal spotting, post-operative fatigue, mild nausea	10% – 30%	Multimodal oral analgesics, short-term rest, antiemetics
Uncommon	Surgical site infection, urinary tract infection, localized hematoma, febrile morbidity	2% – 8%	Targeted oral/IV antibiotics, localized wound care, clinical observation
Rare / Serious	Severe hemorrhage requiring blood transfusion, damage to bladder/bowel/ureter, deep vein thrombosis (DVT), emergency hysterectomy	0.5% – 2%	Blood product administration, intraoperative organ repair, anticoagulation, emergency surgical intervention
Long-Term Risk	Pelvic adhesion formation, fibroid recurrence, uterine rupture during future pregnancy	Recurrence: 15%–30% at 5 years	Adhesion barriers, planned elective Cesarean section at term

A primary long-term clinical consideration is the risk of uterine rupture during subsequent pregnancies. Deep intramural excision that penetrates the full thickness of the myometrium or enters the endometrial cavity alters uterine wall integrity. Clinical guidelines from ACOG recommend elective Cesarean delivery between 37 and 39 weeks of gestation for individuals with prior deep myometrial incisions to eliminate the risk of intrapartum scar rupture (ACOG Practice Bulletin No. 228, 2021).

13. Lifestyle and Behavioural Considerations

Pre-operative optimization and post-operative lifestyle modifications support healing and reduce surgical risk.

Prior to surgery, patients are advised to maintain a balanced diet rich in iron and vitamin C to optimize red blood cell synthesis and support wound healing. Smoking cessation is required for at least 4 weeks prior to surgery to minimize pulmonary complications and microvascular tissue ischemia. Weight optimization through moderate physical activity improves surgical exposure and reduces anaesthetic risk.

During recovery, strict adherence to lifting restrictions (no items over 10 pounds for 4 to 6 weeks following laparotomy) prevents incisional hernia formation and disruption of myometrial repair. Constipation must be avoided by maintaining adequate hydration and consuming high-fiber foods or stool softeners, as straining increases intra-abdominal pressure. High-impact cardiovascular training, core abdominal exercises, and pelvic penetrative activity must be avoided until formal surgical clearance is granted at the post-operative visit.

14. How Outcomes Are Measured

Clinical success following myomectomy is measured through validated symptom score reduction, restoration of hemoglobin levels, and successful reproductive outcomes.

Primary clinical endpoints include:

• Resolution of Heavy Bleeding: Measured via PBAC (Pictorial Blood Loss Assessment Chart) scores and normalization of serum hemoglobin and ferritin levels within 3 months post-procedure.
• Symptom Severity and Quality of Life: Evaluated using the validated Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire, where a significant reduction in symptom severity scores indicates surgical success.
• Anatomical Restoration: Confirmed via follow-up pelvic ultrasonography showing resolution of uterine mass effect and baseline endometrial restoration.
• Reproductive Endpoints: Successful intrauterine pregnancy rates and live birth rates in patients presenting with fibroid-related subfertility. Peer-reviewed cohort data indicate clinical pregnancy rates ranging from 40% to 60% within 12 to 24 months post-myomectomy in patients with cavity-distorting fibroids (ASRM Practice Committee, 2021).

If new symptomatic fibroids develop over time due to de novo tumor formation from previously microscopic smooth muscle rests, secondary medical therapy or repeat conservative or definitive surgical procedures may be evaluated.

15. Recent Advances and Current Standard of Care

The standard of care for myomectomy has evolved significantly over the past 15 years, transitioning away from open abdominal surgery toward minimally invasive approaches.

Key technological and clinical advances include:

• Robotic-Assisted Surgical Systems: High-definition 3D visualization and wristed surgical instrumentation enable precise multi-layer myometrial suturing during minimally invasive excision of complex, deep-seated intramural fibroids.
• Contained Tissue Morcellation: To mitigate the risk of occult leiomyosarcoma dissemination, modern minimally invasive surgery utilizes contained in-bag morcellation protocols within heavy-duty retrieval bags, balancing minimally invasive benefits with oncologic safety (ACOG Practice Bulletin No. 228, 2021).
• Adhesion Barrier Formulations: Intraoperative application of bioresorbable hyaluronic acid-carboxymethylcellulose or oxidized regenerated cellulose barriers over myometrial incisions significantly reduces post-operative pelvic adhesion formation (Bhave Chittawar et al., Cochrane Database Syst Rev, 2014).
• Contemporary Hemostatic Agents: Direct myometrial infiltration with vasopressin combined with topical thrombin matrices has substantially reduced intraoperative blood loss and transfusion requirements.

16. Common Myths and Misconceptions

Addressing common patient misconceptions regarding myomectomy is essential for informed clinical decision-making.

Myth: Fibroids always require surgical removal as soon as they are diagnosed.
Reality: Asymptomatic fibroids identified incidentally on imaging do not require surgical excision. Clinical guidelines recommend observation with periodic clinical evaluation unless symptoms develop or fibroids distort the uterine cavity in patients desiring pregnancy (ACOG Practice Bulletin No. 228, 2021).

Myth: Having a myomectomy means a woman can never give birth naturally in the future.
Reality: Vaginal birth remains possible following hysteroscopic myomectomy or superficial subserosal fibroid removal. Elective Cesarean delivery is only indicated when the surgical incision penetrated deeply into the myometrium or breached the endometrial cavity (ASRM Practice Committee, 2021).

Myth: Myomectomy permanently cures uterine fibroids.
Reality: Myomectomy removes existing fibroids but does not alter the underlying genetic predisposition or hormonal environment. The overall recurrence rate for new fibroids is approximately 15% to 30% within 5 years post-surgery.

Myth: A hysterectomy is safer and easier than a myomectomy.
Reality: While hysterectomy eliminates the risk of fibroid recurrence, myomectomy preserves uterine anatomy, pelvic floor integrity, and reproductive capacity, carrying comparable overall surgical complication rates when performed by experienced clinicians.

Myth: Fibroids are cancerous tumors that can spread.
Reality: Uterine fibroids are completely benign smooth muscle tumors. They do not transform into malignant leiomyosarcomas, which arise independently through distinct genetic pathways.

Myth: Robotic myomectomy is always superior to standard laparoscopic myomectomy.
Reality: Clinical studies demonstrate equivalent surgical outcomes, complication rates, and pregnancy outcomes between robotic and traditional laparoscopic myomectomy when performed by skilled laparoscopic surgeons (ACOG Practice Bulletin No. 228, 2021).

17. Frequently Asked Questions

How long does a myomectomy surgical procedure take?

A myomectomy procedure typically requires 1 to 3 hours to complete. Operative duration depends on the surgical approach (hysteroscopic, laparoscopic, robotic, or open), total number of fibroids, individual tumor sizes, and complexity of the required uterine reconstruction.

Will myomectomy cause early menopause?

No, myomectomy does not cause early menopause. The procedure removes fibroid tissue from the myometrium while leaving both ovaries fully intact. Estrogen and progesterone production by the ovaries continues normally after surgery.

How long after myomectomy can I try to get pregnant?

Clinicians generally recommend waiting 3 to 6 months after myomectomy before attempting conception. This interval allows complete healing and collagen maturation of the myometrial surgical scar, reducing the risk of uterine rupture during pregnancy.

Is a Cesarean section mandatory after myomectomy?

A Cesarean section is only required if the myomectomy involved deep entry into the myometrial muscle layer or breached the endometrial cavity. Superficial subserosal or hysteroscopic fibroid removals do not necessitate routine Cesarean delivery.

What is the risk of fibroids coming back after surgery?

The recurrence rate of new fibroids following myomectomy ranges between 15% and 30% over a 5-year period. Recurrence depends on individual hormonal factors, age, and baseline predisposition to leiomyoma growth.

How much blood loss occurs during a myomectomy?

Average intraoperative blood loss ranges from 50 mL to 300 mL depending on fibroid volume. Hemostatic measures, including pre-operative GnRH therapy and intraoperative vasopressin injection, minimize bleeding during tumor enucleation.

Can a myomectomy be performed during pregnancy?

Myomectomy is avoided during pregnancy due to the high risk of severe hemorrhage and pregnancy loss. Surgical intervention during gestation is strictly reserved for rare instances of severe, unmanageable pain caused by fibroid red degeneration refractory to medical therapy.

How long do I need to stay off work after myomectomy?

Time off work varies by surgical approach: 2 to 3 days for hysteroscopic myomectomy, 2 to 4 weeks for laparoscopic or robotic procedures, and 6 to 8 weeks for open abdominal myomectomy involving laparotomy.

What is the difference between myomectomy and uterine artery embolization?

Myomectomy physically excises fibroid tissue from the uterus while preserving fertility. Uterine artery embolization blocks blood flow to cause fibroid shrinkage and is primarily recommended for individuals who do not plan future pregnancies.

Will myomectomy improve my chances of getting pregnant?

Yes, removing cavity-distorting submucosal or intramural fibroids restores normal uterine anatomy and endometrial receptivity, significantly improving pregnancy rates in individuals experiencing fibroid-related subfertility.

Is myomectomy safe for large fibroids over 10 centimeters?

Yes, myomectomy is safe for large fibroids. Large lesions (>10 cm) are often managed via open abdominal myomectomy or experienced robotic surgery to ensure complete removal and precise, robust multi-layer uterine closure.

What type of anaesthesia is used for myomectomy?

Laparoscopic, robotic, and abdominal myomectomies are conducted under general endotracheal anaesthesia. Hysteroscopic myomectomy can be performed under deep conscious sedation, regional anaesthesia, or general anaesthesia depending on procedure complexity.